
TVRD Stock Forecast & Price Target
TVRD Analyst Ratings
Bulls say
Tvardi Therapeutics is a promising company with a positive outlook due to the potential expansion of their drug TTI-109 into multiple disease indications, along with the positive results of TTI-101 in Phase 1 trials for HCC and IPF. The company's focus on targeting STAT3, along with potential growth opportunities through partnerships and indication expansion, make it a strong candidate for investment. However, there are potential risks with regulatory approval and competition in the commercial market.
Bears say
Tvardi Therapeutics is a biopharmaceutical company that is focused on developing novel, oral, small molecule therapies for diseases with unmet need. While the company's pipeline includes two oral, small molecule STAT3 inhibitors, their lead program TTI-109 is still in early clinical trials and may face challenges in proving its efficacy. Additionally, the company has faced a clinical setback in their Phase 2 trial for idiopathic pulmonary fibrosis, raising concerns about their ability to successfully develop their drugs. Considering the challenges and uncertainties surrounding Tvardi's pipeline and clinical development, the financial analyst has a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TVRD Analyst Forecast & Price Prediction
Start investing in TVRD
Order type
Buy in
Order amount
Est. shares
0 shares